BioMedWire Stocks

UPS Looks to Tap e-Commerce Revenue Through Strategic Acquisitions

The United Postal Service (UPS) recently announced that it will spend more than $1 billion this quarter on the acquisition of two companies to increase its reach in e-commerce and bolster its revenue. Currently the largest parcel delivery firm on the globe, UPS has been grappling with increasing competition from rival delivery companies such as FedEx, DHL, DB Schenker and the federal agency United States Postal Service.

In late October, UPS cut its revenue projections for the year citing lower demand in the e-commerce sector. The impending $1 billion acquisitions are most likely an attempt by UPS to boost its e-commerce sales volumes and increase profits.

Last week, UPS said it had signed an agreement to purchase Happy Returns, a platform that offers box-free returns to hundreds of merchant customers, from PayPal. A month before that, the parcel delivery giant signaled that it intended to buy MNX Global Logistics, a healthcare specialist that offers global logistics and shipping services.

UPS recently completed the acquisition of MNX Global Logistics and is actively working to regain the customers it lost during the U.S. labor talks. The parcel delivery company saw its average daily package volume drop by close to 10% as many customers switched to FedEx during the tumultuous talks.

According to former UPS executive and University of Tennessee Global Supply Chain Institute distinguished fellow Alan Amling, the company’s high-cost network requires a high-margin business to be financially feasible.

Analysts believe Happy Returns could deliver the high margins UPS desperately needs as it operates in the profit-heavy parts of the relatively low-margin e-commerce delivery market.

CEO Carol Tome says the company is putting “the pedal to the metal” with the Happy Returns acquisition as online order returns are a huge business. Around 20% to 30% of all online retail purchases are returned at an average cost of $33 per return, Tome said. Company executives say the Happy Returns acquisition will allow UPS to reduce product return costs for its customers and UPS itself by combining returned products that would have been transported separately.

UPS notes that around 5,200 store locations around the world and more than 12,000 locations in the country will join Happy Return’s designated drop-off points.

Amling says the Happy Situation will put significant pressure on FedEx. The MNX acquisition will also put FedEx in a tough spot as it will expand UPS’s reach in the healthcare segment where FedEx also operates. MNX’s specialty is shipping temperature-controlled products such as cancer drugs and vaccines as well as radiopharmaceuticals that are used to diagnose and treat various diseases, giving UPS access to a segment with extremely high margins.

The foray of UPS into healthcare e-commerce suggests that healthcare e-commerce companies such as NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW) could see the entities they work with making use of the expanded service offerings of UPS to this segment.

NOTE TO INVESTORS: The latest news and updates relating to NextPlat Corp. (NASDAQ: NXPL) are available in the company’s newsroom at https://ibn.fm/NXPL

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Innovative RTNova Platform Research, Exemplifies Pivotal Role of Research

“Research on the treatment of cancer is fundamental to improving outcomes for all patients affected…

1 day ago

Adageis Offering Comprehensive Healthcare AI Tools to Support Profitable Shift to Value-Based Care

Adageis offers an AI-powered financial technology platform tailored to healthcare providers seeking a financially positive…

5 days ago

Scientists ID Bacteria That Could Be Behind Multiple Sclerosis Development

A new study focusing on twins has found that individuals with a larger presence of…

5 days ago

How Stem Cells Help in Blood Cancer Treatment

Stem cells are the “master cells” within the body because they can grow into any…

6 days ago

UnitedHealth Records Lower Revenue as Medical Advantage Use Grows

UnitedHealth Group, the largest health insurance firm in the U.S., has reduced its revenue forecast…

1 week ago

Nutriband Inc. (NASDAQ: NTRB): Building a Moat Around Abuse-Deterrent Drug Delivery

Nutriband secures new U.S. trademark and international patents for AVERSA(TM) platform AVERSA(TM) Fentanyl targets $80M–$200M…

1 week ago